Hoth Therapeutics Files 8-K: Administrative Update, Nasdaq Listing Confirmed

TL;DR

**Hoth Therapeutics filed an administrative 8-K, confirming its Nasdaq listing; no new material news.**

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on January 9, 2024, reporting an 'Other Event' that occurred on January 8, 2024. This filing primarily serves to update administrative information, such as confirming its common stock trades under the symbol HOTH on The Nasdaq Stock Market LLC. For investors, this filing is largely administrative and does not contain new financial or operational news that would significantly impact the stock's value, but it confirms the company's continued listing on a major exchange.

Why It Matters

This filing is mainly administrative, confirming Hoth Therapeutics' listing on Nasdaq, which is important for liquidity and investor confidence, but it doesn't contain new material financial or operational news.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial or operational risks to the company.

Analyst Insight

A smart investor would note this administrative filing confirms Hoth Therapeutics' continued listing on Nasdaq, which is a standard operational detail, but would not expect any immediate stock price movement based solely on this non-material update.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where Hoth Therapeutics' common stock is registered
• HOTH (other) — the trading symbol for Hoth Therapeutics' common stock
• January 8, 2024 (date) — date of the earliest event reported
• January 9, 2024 (date) — date the 8-K was filed

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar

Filing Documents

• ea191413-8k_hoththera.htm (8-K) — 23KB
• 0001213900-24-002248.txt ( ) — 193KB
• hoth-20240108.xsd (EX-101.SCH) — 3KB
• hoth-20240108_lab.xml (EX-101.LAB) — 33KB
• hoth-20240108_pre.xml (EX-101.PRE) — 22KB
• ea191413-8k_hoththera_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On January 8, 2024 Hoth Therapeutics filed a patent application with the U.S. Patent and Trademark Office ("USPTO") for the use of a therapeutic for weight loss (obesity) and the side effects associated with certain weight loss (obesity) therapeutics. Obesity is a disorder characterized by the accumulation of excess fat in the body. Obesity has been recognized as one of the leading causes of disease and is emerging as a global problem. Various methods of treating obesity and related conditions, involve administering certain medications or combinations thereof. For example, a number of references disclose the administration of certain weight loss medications that include an anticonvulsant, an opioid antagonist, glucagon-like peptide 1 (GLP-1) receptor agonist and/or a norepinephrine reuptake inhibitor (NRI) to a patient in need thereof to affect weight loss. However, the administration of weight loss medications often incurs adverse side effects. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 9, 2024 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR